Long-term treatment of refractory invasive fungal infection with posaconazole: additive value of therapeutic drug monitoring

Long-term treatment of refractory invasive fungal infection with posaconazole: additive value of therapeutic drug monitoring

Posaconazole is a recently developed broad-spectrum triazole antifungal with potential for long-term prophylaxis or therapy of invasive fungal infections. This case illustrates the additive value for therapeutic drug monitoring to guide clinical decision-making in high risk patients.

Saved in:
Bibliographic Details
Published in:Acta clinica belgica (English ed. Online) Vol. 66; no. 3; pp. 231 - 232
Main Authors: Henckaerts, L, Spriet, I, Meersseman, W, Peetermans, W E
Format: Journal Article
Language:English
Published: England Acta Clinica Belgica 01-05-2011
Taylor & Francis Ltd
Subjects:
Adult
Amphotericin B
Antifungal Agents - administration & dosage
Antifungal Agents - blood
Antifungal Agents - pharmacokinetics
Antiparasitic agents
Aspergillus fumigatus
Biological response modifiers
Chromatography, High Pressure Liquid
Drug Monitoring
Drug therapy
Fungal infections
Granulomatous Disease, Chronic - complications
Granulomatous Disease, Chronic - microbiology
Health aspects
Humans
Infection
Male
Medical treatment
Mycoses
Plasma
Prevention
Pulmonary Aspergillosis - drug therapy
Pulmonary Aspergillosis - etiology
Recurrence
Risk factors
Triazoles
Triazoles - administration & dosage
Triazoles - blood
Triazoles - pharmacokinetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Posaconazole is a recently developed broad-spectrum triazole antifungal with potential for long-term prophylaxis or therapy of invasive fungal infections. This case illustrates the additive value for therapeutic drug monitoring to guide clinical decision-making in high risk patients.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1784-3286
2295-3337
DOI:10.2143/ACB.66.3.2062555